Found 14 articles
Since the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks. Now some companies are in the testing phase for just that.
Hyundai Bioscience announced on the 11th that phase 2 clinical trial of CP-COV03 for COVID-19 patients has begun.
CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants
CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19.
Hyundai Bioscience announced on the 24th that CNPharm, its major shareholding bio tech company, published an article containing the research results of CP-COV03, a Niclosamide-based oral treatment for COVID-19 based on its proprietary oral formulation technology, in a special issue of Pharmaceuticals.
New study indicating Niclosamide as 'COVID-19 game changer' was unveiled at Science Council of Asia Conference
Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major shareholding bio tech company, CNPharm's single administration of 'Poly-COV01', which was developed as an injection for severely ill patients with the novel coronavirus infection (COVID- 19),
A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection, was published in the world-renowned SCI -level international journal and is attracting international attention.
Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for the potential treatment of patients with severe cases of COVID-19
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem
Hyundai Bioscience (KOSDAQ symbol: 048410) released a report on December 8 th that CP-COV03 , its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activity with a single administration. This pharmacokinetics study was recently p
Expectations are increasing as a Korean bio-tech company has succeeded in solving the problem of low absorption which has been one of the biggest obstacles for the repositioning of Niclosamide, an anthelmintic, as the first orally ingested treatment for COVID-19.
There has been an increase in the possibility for the 'conquering of cancer' as test results confirm, for the first time, the disappearance of tumors upon administering a 'pain-free anticancer drug.'
Hyundai Bioscience Unveils New Cancer Treatment that Offers Tumor Elimination without Painful Side Effects
At the 2019 Global Bio Conference, the company released preliminary test results, achieving an 'almost full regression of pancreatic cancer' in animal testing
Acerus Pharmaceuticals Corporation reported its financial results for the three months and six months ended June 30, 2018. Unless otherwise noted, all amounts are in U.S. dollars.